FSD Pharma Inc, (CSE:HUGE) (“FSD” or the “Company”), is pleased to report that on September 11, 2018 the Company traded an aggregate total of exactly 213,761,823 shares. FSD traded 143,260,988 Class B subordinate voting shares on the Canadian Securities Exchange (“CSE”), 1,888,500 on AQC-Lit, 15,369,000 on AQC-Neo, 241,740 on CXC, 5,309,399 on CX2, 6,473,592 on CXD, 22,500 on Lynx, 24,750,500 on Omega and 16,445,604 on MatchNow. This is the largest total quantity of share volume traded by a CSE listed issuer by over 15.7% above the recorded all-time high of 184,718,114 also achieved by FSD on September 10, 2018, as confirmed by the CSE. This record is also 41% over the Company’s previous reporting of achieving an all-time high of 151,183,895 on September 4, 2018.
The company wishes to again thank all its shareholders and stakeholders for their support to date, which has resulted in yet another record-breaking achievement in the Canadian cannabis investment marketplace.
About FSD Pharma Inc.
FSD Pharma, owns, through its wholly-owned subsidiary FV Pharma Inc., a license to produce marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) which was originally granted on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour’s drive from Toronto, FSD Pharma’s management’s mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. FSD Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts and research and development. Please visit www.fsdpharma.com for more information.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the development of the Corporation’s indoor cannabis facility and its business goals and objectives. The forward-looking information contained in this press release is made as of the date hereof, and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.
Neither the Canadian Securities Exchange nor its regulation services provider accept responsibility for the adequacy or accuracy of this release.
For further information: Anthony Durkacz, Director, FSD Pharma Inc., email@example.com, 416-720-4360; Investor Relations: Email: IR@fsdpharma.com, Website: www.fsdpharma.com